European Association for the Study of the Liver Congress 2026 (EASL 2026)

Patients with primary sclerosing cholangitis (PSC) who received norucholic acid (NCA), with or without ursodeoxycholic acid (UDCA) background therapy, were more likely to achieve histological and biochemical improvements than those receiving placebo, according to the subgroup analysis of the NUC-5 trial presented at EASL 2026.

Treatment with pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist, led to significant improvements in primary noninvasive tests (NITs), such as Enhanced Liver Fibrosis (ELF) and Liver Stiffness Measurement (LSM), and weight loss in patients with metabolic dysfunction-associated steatohepatitis (MASH), according to the phase IIb IMPACT trial presented at EASL 2026.

The investigational ileal bile acid transporter (IBAT) inhibitor volixibat provides rapid and sustained improvement in pruritus in patients with primary sclerosing cholangitis, according to the topline results of the VISTAS study.

The novel antisense oligonucleotide bepirovirsen has induced functional cure in one-fifth of patients with chronic hepatitis B virus (HBV) infection in the phase 3 B-Well 1 and B-Well 2 trials.

Individuals with chronic hepatitis D (CHD) may benefit from lonafarnib boosted with ritonavir (LNF/RTV) alone or in combination with peg-interferon-alfa (PEG), findings from the phase III D-LIVR trial have shown.